EUROPEAN RENAL ASSOCIATION - EUROPEAN DIALYSIS AND TRANSPLANT ASSOCIATION
Services
How to use the platform
Build a poster
MANAGE ORDERS
FAQs
Contact
HOMEPAGE
Virtual Poster Gallery
PrintingOnline for Collection on-site
Accredited Training
DOI - Digital Object Identifier
What is PosterSessionOnline?
How to send your poster
How to visit the Virtual Poster Gallery
How to build a poster
How to reduce a poster to less than 2 Mb
PosterSessionOnline Image Editor
How to build a poster with our templates
How to work with a template
Templates and instructions
Discussion forum -
49th ERA-EDTA Congress
Topic -
Clinical Nephrology - Epidemiology I
If you are already registered in PosterSessionOnline, enter your e-mail and click on LOGIN. Otherwise click on REGISTER.
Poster:
108
Visits:
656
Title:
EFFICACY AND SAFETY OF ORAL FEBUXOSTAT IN SUBJECTS WITH MODERATE-TO-SEVERE CHRONIC KIDNEY DISEASE (CKD): A PILOT STUDY
Authors:
Vassilis Filiopoulos ,
Centre:
Amalia Fleming General Hospital, Athens, Greece
You must be registered to reply or comment.
EFFICACY AND SAFETY OF ORAL FEBUXOSTAT IN SUBJECTS WITH MODERATE-TO-SEVERE CHRONIC KIDNEY DISEASE (CKD): A PILOT STUDY
Vassilis Filiopoulos
Thread initiator
Subspeciality
Reg:
12/14/2011 9:54:00 PM
Comment# 1
I invite healthcare professionals to open debate around the issues raised in my poster, both those relating to research and to clinical practice.
Comment added on 4/25/2012 1:09:00 AM
You must be registered to reply or comment.
Most viewed poster for this congress
Poster:
424
Visits:
2808
Title:
Neutrophil Gelatinase-Associated Lipocalin (NGAL) in Glomerulonephritides: an Immunohystochemical expression analysis
Authors:
Giuseppe Coppolino ,
Centre:
Chair of Nephrology, University Magna Graecia of Catanzaro, Catanzaro, Italy
Poster most viewed in this topic
Poster:
88
Visits:
1209
Title:
Renoprotective effects of spironolactone in patients with proteinuric kidney diseases
Authors:
ENRIQUE MORALES ,
Centre:
HOSPITAL 12 DE OCTUBRE
View Poster Gallery
Back to congress home
Other Congresses
About us
|
Terms and Conditions
|
Special Access